Skip to main content

Celgene expands New Jersey manufacturing centre

US-based biotechnology company Celgene has completed the first phase of a renovation at its Summit West campus in New Jersey that will house a state-of-the-art cellular immunotherapy manufacturing centre.

The 135,000ft2 facility was completed months ahead of the original plan and will enable the company to expand investigation programmes and eventually the potential commercial launch related to bb2121, its chimeric antigen receptor (CAR T) therapy being developed for certain multiple myeloma patients in conjunction with its partner bluebird bio.

Add new comment

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.